Name | Value |
---|---|
Revenues | 160.3M |
Cost of Revenue | 49.0M |
Gross Profit | 111.3M |
Operating Expense | 102.3M |
Operating I/L | 12.1M |
Other Income/Expense | -23.4M |
Interest Income | 3.1M |
Pretax | -26.5M |
Income Tax Expense | -6.9M |
Net Income/Loss | -19.5M |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions in the United States. The company's flagship products include EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used for targeted nerve treatment. Additionally, Pacira BioSciences develops proprietary multivesicular liposome drug delivery technology, encapsulating drugs without altering their molecular structure.